Abstract
We developed a novel analytic pipeline - FastMix - to integrate flow cytometry, bulk transcriptomics, and clinical covariates for statistical inference of cell type-specific gene expression signatures. FastMix addresses the “large p, small n” problem via a carefully designed linear mixed effects model (LMER), which is applicable for both cross-sectional and longitudinal studies. With a novel moment-based estimator, FastMix runs and converges much faster than competing methods for big data analytics. The pipeline also includes a cutting-edge flow cytometry data analysis method for identifying cell population proportions. Simulation studies showed that FastMix produced smaller type I/II errors with more accurate parameter estimation than competing methods. When applied to real transcriptomics and flow cytometry data in two vaccine studies, FastMix-identified cell type-specific signatures were largely consistent with those obtained from the single cell RNA-seq data, with some unique interesting findings.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT03083158
Funding Statement
This work is partially funded by NIH/NIAID UH2AI132342, the Human Vaccines Project, the Respiratory Pathogens Research Center (NIAID contract number HHSN272201200005C) and the University of Rochester CTSA award number UL1 TR002001 from the National Center for Advancing Translational Sciences of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
University of British Columbia Human Research Ethics Committee and Internal Review Board (IRB) have provided approval for the clinical trial NCT03083158 (PI: Tobias Kollmann; Title: Identification of Age-dependent Mechanism of Vaccine-induced Immunity to a Single Dose of Hepatitis B Vaccine Using a Systems Biology Approach - a Demonstration Project). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. For SDY180, data are publicly available after registration with ImmPort.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The HVP01 dataset (https://clinicaltrials.gov/ct2/show/NCT03083158) is a clinical study conducted by University of British Columbia focused on Hepatitis B vaccine Engerix-B. This study has 16 healthy subjects from two cohorts: young adults (aged 40-60) and old adults (aged 61-80). Both RNA-seq gene expressions and flow cytometry data are available across multiple visits before and after the vaccination from the same whole blood samples. Primary outcome of this study is the antibody response to the first dose of Hepatitis B vaccine. The SDY180 dataset is downloaded from the ImmPort Shared Data portal (http://www.immport.org). This study has 18 young and healthy adult volunteers (aged 18-64) randomly assigned to three study groups (n = 6 subjects/group) receiving a single intramuscular dose of 2009-2010 seasonal influenza (Fluzone, Sanofi Pasteur, PA), pneumococcal vaccine (Pneumovax23, Merck, NJ), or placebo (saline). Blood samples were collected at multiple time visits, from 7 days before vaccination to 28 days after vaccination, for microarray, whole-blood flow cytometry, and serum analysis of neutralizing antibodies. Data preprocessing details are in Supplementary Material.
